These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 39229471)

  • 1. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.
    Almansour SA; Alqudah MAY; Abuhelwa Z; Al-Shamsi HO; Alhuraiji A; Semreen MH; Bustanji Y; Alzoubi KH; Modi ND; Mckinnon RA; Sorich MJ; Hopkins AM; Abuhelwa AY
    Ther Adv Med Oncol; 2024; 16():17588359241275387. PubMed ID: 39229471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.
    Kahale LA; Matar CF; Tsolakian I; Hakoum MB; Yosuico VE; Terrenato I; Sperati F; Barba M; Hicks LK; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD014739. PubMed ID: 34582035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.
    Pandor A; Horner D; Davis S; Goodacre S; Stevens JW; Clowes M; Hunt BJ; Nokes T; Keenan J; de Wit K
    Health Technol Assess; 2019 Dec; 23(63):1-190. PubMed ID: 31851608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic anticoagulants for non-hospitalised people with COVID-19.
    Santos BC; Flumignan RL; Civile VT; Atallah ÁN; Nakano LC
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD015102. PubMed ID: 37591523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding.
    Chang WH; Mueller SH; Tan YY; Lai AG
    Lancet Reg Health Eur; 2021 Nov; 10():100222. PubMed ID: 34806071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.
    Middleton P; Shepherd E; Gomersall JC
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001689. PubMed ID: 33779986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
    Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N
    Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
    Parnes A; Leblebjian H; Hamilton J; Smith S; Laubach J; Berliner N
    J Oncol Pharm Pract; 2022 Mar; 28(2):421-424. PubMed ID: 33611974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
    Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.
    Robertson L; Ghouri MA; Kovacs F
    Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002071. PubMed ID: 22895926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
    Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
    Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.